Volition Signs Exclusive $28 million License and Supply Agreement with Heska

Good Call Media filmed in Las Vegas, USA, to prepare the way for a major new announcement by our clients, New York Stock Exchange-quoted Volition RX.

Long, drawn out, expensive tests are not what you want if you suspect your dog has cancer.

So many congratulations to Volition Vet, who after many years of scientific endeavour, signed an exclusive global supply and licensing agreement with Heska Corporation to distribute their Nu.Q® Vet Cancer Screening Test.   This will enable vets to screen for cancer in dogs using Volition’s simple blood test and one of Heska’s point of care test systems, receiving the results in their surgery right there and then.

“We are thrilled to announce this agreement with Heska, a company dedicated to developing the next generation of rapid, highly affordable, point-of-care diagnostics for companion animals,” commented Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC.

“As such, we want to make our Nu.Q® Vet Cancer Screening Test as accessible as possible to veterinarians around the world, ensure cancer is detected earlier, and improve outcomes for pets and pet owners.”

Watch our film to hear more from Dr Tom Butera and Volition’s new partner Heska’s CEO Kevin Wilson.